REVERSAL OF MULTIPLE-DRUG RESISTANCE IN-VITRO BY PHOSPHORATHIOATE OLIGONUCLEOTIDES AND RIBOZYMES

被引:38
作者
BERTRAM, J [1 ]
PALFNER, K [1 ]
KILLIAN, M [1 ]
BRYSCH, W [1 ]
SCHLINGENSIEPEN, KH [1 ]
HIDDEMANN, W [1 ]
KNEBA, M [1 ]
机构
[1] MPI BIOPHYS & CHEM,D-37075 GOTTINGEN,GERMANY
关键词
ANTISENSE OLIGONUCLEOTIDES; MULTIPLE DRUG RESISTANCE; P-GLYCOPROTEIN; RIBOZYMES;
D O I
10.1097/00001813-199502000-00015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the present study we investigated the effectiveness of 14, 15 and 18 nucleotide antisense phosphorothioate oligonucleotides (S-ODNs) directed to four different regions of the published mdr-1 gene sequence to reduce the level of mdr-1 gene product (p170, P-glycoprotein) and its function in the over-expressing cell lines LoVoDx(R), S180Dx(R) and KBCh(R)8-5. The highest efficiency in reduction of multiple drug resistance was obtained at a concentration of 2 mu M. In proliferation assays a growth reduction of 50% was observed after exposure of doxorubicin-resistant cells to S-ODN3. p170 protein expression of the resistant cell line LoVoDx(R) was reduced to the level of the sensitive cell line LoVo as shown by Western blot analysis. S-ODN3 reduced the ID50 of the two human cell lines up to 60% (LoVoDx(R)) and 21% (KBCh(R)8-5), respectively, but showed no effect in the murine cell line S180Dx(R). In contrast, S-ODN1 was most effective in the murine system (67% reduction of the ID50), less effective in LoVoDx(R) (34%) and exhibited no effect in cell line KBCh(R)8-5. Based on the results with the antisense oligonucleotides, a ribozyme directed against the mRNA target region of S-ODN3 was designed. This ribozyme was able to reduce the mdr-1 mRNA in total RNA preparations from cell line LoVoDx(R) up to 80% after an incubation time of 6 h in the presence of 10 mM MgCl2 at pH 7.5. A modified ribozyme was investigated in cell culture and reduced chemo-resistance of the resistant cell line LoVoDx(R) and ex vivo cultured blasts of acute myeloid leukemia patients up to 50%.
引用
收藏
页码:124 / 134
页数:11
相关论文
共 32 条
[1]  
BELLAMY WT, 1988, CANCER RES, V48, P6303
[2]   REDUCTION OF ERBB2 GENE-PRODUCT IN MAMMA CARCINOMA CELL-LINES BY ERBB2 MESSENGER-RNA-SPECIFIC AND TYROSINE KINASE CONSENSUS PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDES [J].
BERTRAM, J ;
KILLIAN, M ;
BRYSCH, W ;
SCHLINGENSIEPEN, KH ;
KNEBA, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 200 (01) :661-667
[3]  
BRADLEY G, 1989, CANCER RES, V49, P2790
[4]  
BUDOWLE B, 1991, BIOTECHNIQUES, V7, P736
[5]   ANTISENSE TECHNOLOGY FOR CANCER-THERAPY - DOES IT MAKE SENSE [J].
CARTER, G ;
LEMOINE, NR .
BRITISH JOURNAL OF CANCER, 1993, 67 (05) :869-876
[6]   ISOLATION OF BIOLOGICALLY-ACTIVE RIBONUCLEIC-ACID FROM SOURCES ENRICHED IN RIBONUCLEASE [J].
CHIRGWIN, JM ;
PRZYBYLA, AE ;
MACDONALD, RJ ;
RUTTER, WJ .
BIOCHEMISTRY, 1979, 18 (24) :5294-5299
[7]   DRUG-RESISTANCE IN MULTIPLE-MYELOMA AND NON-HODGKINS LYMPHOMA - DETECTION OF P-GLYCOPROTEIN AND POTENTIAL CIRCUMVENTION BY ADDITION OF VERAPAMIL TO CHEMOTHERAPY [J].
DALTON, WS ;
GROGAN, TM ;
MELTZER, PS ;
SCHEPER, RJ ;
DURIE, BGM ;
TAYLOR, CW ;
MILLER, TP ;
SALMON, SE .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (04) :415-424
[8]   D-VERAPAMIL DOWN-MODULATES P170-ASSOCIATED RESISTANCE TO DOXORUBICIN, DAUNORUBICIN AND IDARUBICIN [J].
DAMIANI, D ;
MICHIELI, M ;
MICHELUTTI, A ;
MELLI, C ;
CERNO, M ;
BACCARANI, M .
ANTI-CANCER DRUGS, 1993, 4 (02) :173-180
[9]   REVERSAL OF DRUG-RESISTANCE IN MULTIPLE-MYELOMA WITH VERAPAMIL [J].
DURIE, BGM ;
DALTON, WS .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 68 (02) :203-206
[10]  
EFFERTH T, 1993, ONCOLOGY, V50, P303